TransMedics Group, Inc. (TMDX) FCF Payout Ratio: N/A
The FCF payout ratio for TransMedics Group, Inc. (TMDX) is N/A.
TMDX FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
Payout Ratio Comparison
FCF Payout Ratio
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
5.31%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $133.59M | $0 | 0.0% |
| 2024 | ($80.94M) | $0 | N/A (Loss) |
| 2023 | ($192.09M) | $0 | N/A (Loss) |
| 2022 | ($57.72M) | $0 | N/A (Loss) |
| 2021 | ($32.38M) | $0 | N/A (Loss) |
| 2020 | ($30.72M) | $0 | N/A (Loss) |
| 2019 | ($32.45M) | $0 | N/A (Loss) |
| 2018 | ($26.40M) | $0 | N/A (Loss) |
| 2017 | ($23.36M) | $0 | N/A (Loss) |
| 2016 | ($25.59M) | $0 | N/A (Loss) |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
TransMedics Group, Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein